Elizabeth G. O’Farrell's most recent trade in SpyGlass Pharma Inc. was a trade of 13,700 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpyGlass Pharma Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 13,700 | 13,700 | - | - | Stock Option (right to buy) | |
| LENSAR Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 7,374 | 49,947 | - | 0 | Common Stock | |
| Geron Corp | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Geron Corp | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| LENSAR Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 22,000 | 42,573 | - | 0 | Common Stock | |
| Geron Corp | Elizabeth G. O’Farrell | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 24 Aug 2023 | 6,607 | 7,407 (0%) | 0% | 2.3 | 15,064 | Common Stock |
| Geron Corp | Elizabeth G. O’Farrell | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 24 Aug 2023 | 6,579 | 26,220 (0%) | 0% | 2.3 | 15,000 | Common Stock |
| Geron Corp | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| LENSAR Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 33,175 | 33,175 | - | - | Stock Option (Right to Buy) | |
| LENSAR Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,288 | 20,573 | - | 0 | Common Stock | |
| Inhibikase Therapeutics Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 22,677 | 22,677 | - | - | Stock Option (right to buy) | |
| LENSAR Inc | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 20,847 | 20,847 | - | - | Stock Option (Right to Buy) | |
| Geron Corp | Elizabeth G. O’Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 83,000 | 83,000 | - | - | Stock Option (right to buy) |